The Claim
Plasma plasminogen activator inhibitor-1 (PAI-1) concentrations are significantly higher in adults with nonalcoholic fatty liver disease compared to healthy controls and are correlated with both endotoxin levels and hepatic TLR4 expression.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Adults with nonalcoholic fatty liver disease have higher levels of PAI-1 in their blood than healthy individuals, and these higher levels are linked to increased endotoxin in the blood and higher TLR4 activity in the liver.
See the scientific wording
Plasma plasminogen activator inhibitor-1 (PAI-1) concentrations are significantly higher in adults with nonalcoholic fatty liver disease than in healthy controls, and correlate with both endotoxin levels and hepatic TLR4 expression, suggesting a role in liver inflammation.
Bacteria in the gut leak into the bloodstream due to a damaged intestinal barrier, and their toxins reach the liver. These toxins bind to a receptor on liver cells, turning on inflammation signals that cause the liver to produce more PAI-1. This protein builds up in the blood and contributes to fat accumulation and scarring in the liver.
What the research says
1 studyPeople with fatty liver disease had more of a protein called PAI-1 in their blood than healthy people, and that protein was linked to signs of gut bacteria leaking into the liver and triggering inflammation — exactly what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.